Nonproliferative Diabetic Retinopathy

In this Healio Video Perspective from the ASRS meeting, Dilsher Dhoot, MD, of California Retina Consultants discusses interim safety and efficacy results for OTX-TKI for the treatment of nonproliferative diabetic retinopathy.

In this Healio Video Perspective from the ASRS meeting, Margaret Chang, MD, MS, of Retinal Consultants Medical Group presents 2-year results for the port delivery system with ranibizumab.

PARK CITY, Utah — Outcomes from the phase 1/2a HORNBILL study indicate a potential disease-modifying effect of BI 764524 in eyes with diabetic macular ischemia.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Dilsher S. Dhoot, MD, of California Retina Consultants, discusses positive 40-week data from the phase 1 HELIOS trial.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Jay S. Pepose, MD, PhD, of Ocuphire Pharma, discusses an oral small-molecule Ref-1 inhibitor for nonproliferative diabetic retinopathy.

As Healio’s coverage of the Association for Research in Vision and Ophthalmology meeting winds down, catch up on this year’s most popular articles.

A phase 2 clinical study of RZ402, a potential oral therapy for diabetic macular edema, met its primary endpoints of safety and reduction in central subfield thickness, according to a press release from Rezolute.

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Jay S. Duker, MD, of EyePoint Pharmaceuticals discusses lead product Duravyu.

OcuTerra Therapeutics is evaluating strategic alternatives after the phase 2 DR:EAM trial failed to meet its primary efficacy endpoint, according to a press release.

ATLANTA — Ocuphire Pharma shared the status of its oral nonproliferative diabetic retinopathy treatment, APX3330, with the optometry community at SECO 2024.